Nrx Pharmaceuticals Inc (NRXP)

$4.48 +0.02 (0.45%)
Market Cap 151.44M
Revenue (ttm) 1.23M
Net Income (ttm) -28.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,326.83%
Debt to Equity Ratio 0.00
Volume 601,800
Avg Vol 1,255,906
Day's Range N/A - N/A
Shares Out 36.23M
Stochastic %K 82%
Beta 2.19
Analysts Strong Sell
Price Target $39.67

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100,...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 254 6134
Address:
1201 N. Market Street, Suite 111, Wilmington, United States
Tide16
Tide16 Jul. 23 at 12:43 AM
$NRXP Back at it tomorrow, keep the faith!
0 · Reply
Starwanderer
Starwanderer Jul. 22 at 8:26 PM
$NRXP https://www.digitaljournal.com/pr/news/pr-zen/darpa-selects-nrx-pharmaceuticals-defense-133556921.html
2 · Reply
biotrade123
biotrade123 Jul. 22 at 8:00 PM
$NRXP Good Close 👍👍🤞🤞
0 · Reply
biotrade123
biotrade123 Jul. 22 at 6:15 PM
$NRXP giving up gains??
0 · Reply
Outcomes
Outcomes Jul. 22 at 5:27 PM
$NRXP
0 · Reply
djcal
djcal Jul. 22 at 3:24 PM
$NRXP Getting a lot of news and attention NOW. Trial opens for US mum who says postpartum issues led her to killing own children https://www.bbc.com/news/articles/cy8e9jq1lzvo
0 · Reply
LuziusSteiger
LuziusSteiger Jul. 22 at 3:02 PM
$NRXP FDA continues its heavy crackdown on illicit/unapproved Ketamine suppliers! 🚨 > Another Warning Letter dropped (MARCS-CMS 725150) targeting grey-market IV/Inj Ketamine vendors. FDA explicitly highlighting the severe risks of unapproved injectables. The FDA is actively purging the market of illegal & unmonitored supply, effectively paving the way and building a massive moat for fully compliant, cGMP-grade formulations like KETAFREE™ / NRX-100. Clean market + Regulatory enforcement = Massive win for approved pharma. July 29 GDUFA date ahead! 🐂💊
0 · Reply
BioRich
BioRich Jul. 22 at 2:19 PM
$NRXP DARPA (free) money? Let's go $NRXP "On July 21, 2026, NRXD received a letter from the Defense Advanced Research Projects Agency (“DARPA”), Defense Sciences Office (DSO), notifying the Company that its proposal to conduct a clinical trial, entitled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) had been selected by DARPA for negotiation of a potential award." Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $NRXS
1 · Reply
BioRich
BioRich Jul. 22 at 2:16 PM
$NRXP Amazing news out of the $NRXP camp this morning. Anytime alternate funding opportunities arise, it's great for a company (and it's shareholders). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! https://ir.nrxpharma.com/node/11201/html
1 · Reply
djcal
djcal Jul. 22 at 2:07 PM
$NRXP Your a fool if you sell after FDA approval. Other catalyst and you will miss out on the FREE shares of spin-off with Hope Therapeutics. Does anyone INVEST these days or is everything just a penny flip or treated with the stupid "Buy the rumor sell the news" motto. Everyone always taking a penny over a dollar just becaue they can't wait. Buffett 101: "The stock market is a device used to transfer money from the IMPATIENT to the PATIENT.
3 · Reply
Latest News on NRXP
NRx Pharmaceuticals issues response to Kadima statements

2026-06-25T20:15:31.000Z - 27 days ago

NRx Pharmaceuticals issues response to Kadima statements

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

Jun 25, 2026, 4:01 PM EDT - 27 days ago

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Jun 25, 2026, 7:00 AM EDT - 27 days ago

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

Kadima Neuropsychiatry Institute alleges NRx breached contract

2026-06-24T17:25:15.000Z - 4 weeks ago

Kadima Neuropsychiatry Institute alleges NRx breached contract

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

Jun 24, 2026, 1:18 PM EDT - 4 weeks ago

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

Jun 23, 2026, 11:05 AM EDT - 4 weeks ago

ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

ZETA

NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101

2026-06-22T11:18:34.000Z - 4 weeks ago

NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

Jun 22, 2026, 7:00 AM EDT - 4 weeks ago

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

Jun 5, 2026, 8:50 AM EDT - 6 weeks ago

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option

Jun 4, 2026, 5:12 PM EDT - 6 weeks ago

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

2026-06-03T15:17:33.000Z - 7 weeks ago

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

Jun 3, 2026, 8:18 AM EDT - 7 weeks ago

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

NRx Pharmaceuticals announces common stock offering, no amount given

2026-06-02T20:05:59.000Z - 7 weeks ago

NRx Pharmaceuticals announces common stock offering, no amount given

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jun 2, 2026, 4:01 PM EDT - 7 weeks ago

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

May 28, 2026, 7:00 AM EDT - 7 weeks ago

NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

May 27, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals Earnings Call Transcript: Q1 2026

May 18, 2026, 8:00 AM EDT - 2 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q1 2026

NRx Pharmaceuticals Quarterly report: Q1 2026

May 18, 2026, 8:00 AM EDT - 2 months ago

NRx Pharmaceuticals Quarterly report: Q1 2026

NRx Pharmaceuticals Earnings release: Q1 2026

May 18, 2026, 8:00 AM EDT - 2 months ago

NRx Pharmaceuticals Earnings release: Q1 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 18, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

May 14, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

NRx Pharmaceuticals initiated with a Buy at Lucid Capital

2026-05-13T10:11:36.000Z - 2 months ago

NRx Pharmaceuticals initiated with a Buy at Lucid Capital

NRx Pharmaceuticals gets FDA clearance to initiate NRX-101 trial

2026-05-07T18:39:21.000Z - 2 months ago

NRx Pharmaceuticals gets FDA clearance to initiate NRX-101 trial

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

May 7, 2026, 8:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

NRx Pharmaceuticals receives first commercial manufacturing order for ketamine

2026-05-05T13:49:41.000Z - 2 months ago

NRx Pharmaceuticals receives first commercial manufacturing order for ketamine

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

May 5, 2026, 7:00 AM EDT - 2 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

NRx Pharmaceuticals gets FDA feedback on ketamine program

2026-04-22T11:48:51.000Z - 3 months ago

NRx Pharmaceuticals gets FDA feedback on ketamine program

NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

Apr 22, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

White House shift on psychedelics positive for NRx, says D. Boral

2026-04-20T14:07:54.000Z - 3 months ago

White House shift on psychedelics positive for NRx, says D. Boral

NRx Pharmaceuticals welcomes the newly-signed Executive Order

2026-04-20T11:20:02.000Z - 3 months ago

NRx Pharmaceuticals welcomes the newly-signed Executive Order

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

Apr 20, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

Apr 15, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

Apr 13, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

Apr 6, 2026, 7:00 AM EDT - 3 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

NRx Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 4 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q4 2025

NRx Pharmaceuticals Earnings release: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 4 months ago

NRx Pharmaceuticals Earnings release: Q4 2025

NRx Pharmaceuticals Annual report: Q4 2025

Mar 24, 2026, 8:00 AM EDT - 4 months ago

NRx Pharmaceuticals Annual report: Q4 2025

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

Mar 24, 2026, 7:00 AM EDT - 4 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

NRx Pharmaceuticals Transcript: AGM 2026

Mar 23, 2026, 10:00 AM EDT - 4 months ago

NRx Pharmaceuticals Transcript: AGM 2026

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

Mar 19, 2026, 7:00 AM EDT - 4 months ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

Mar 17, 2026, 7:00 AM EDT - 4 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx's Preservative-Free Ketamine Application

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Mar 16, 2026, 7:00 AM EDT - 4 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

Mar 9, 2026, 7:00 AM EDT - 4 months ago

HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

Mar 2, 2026, 7:00 AM EST - 5 months ago

NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 5 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing

NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 23, 2026, 7:00 AM EST - 5 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

Feb 17, 2026, 7:00 AM EST - 5 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx Pharmaceuticals Proxy statement: Proxy Filing

Feb 13, 2026, 7:00 AM EST - 5 months ago

NRx Pharmaceuticals Proxy statement: Proxy Filing

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

Jan 16, 2026, 7:03 AM EST - 6 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

Jan 14, 2026, 7:03 AM EST - 6 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

Jan 5, 2026, 6:57 AM EST - 7 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Dec 18, 2025, 7:05 AM EST - 7 months ago

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

NRx Pharmaceuticals Registration statement: Registration Filing

Dec 12, 2025, 7:00 AM EST - 7 months ago

NRx Pharmaceuticals Registration statement: Registration Filing

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

Dec 3, 2025, 7:00 AM EST - 8 months ago

NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation

NRx Pharmaceuticals Transcript: Study Update

Dec 2, 2025, 9:00 AM EST - 8 months ago

NRx Pharmaceuticals Transcript: Study Update

NRx Pharmaceuticals Press release: Study Update

Dec 2, 2025, 9:00 AM EST - 8 months ago

NRx Pharmaceuticals Press release: Study Update

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

Dec 2, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

Dec 2, 2025, 7:30 AM EST - 8 months ago

NRx Pharmaceuticals (NASDAQ: NRXP) and HOPE Therapeutics to Host Corporate Update Call

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

Dec 1, 2025, 8:03 AM EST - 8 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 - Noble Capital Markets' Twenty First Annual Emerging Growth Equity Conference

NRx Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Earnings Call Transcript: Q3 2025

NRx Pharmaceuticals Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Earnings release: Q3 2025

NRx Pharmaceuticals Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 8 months ago

NRx Pharmaceuticals Quarterly report: Q3 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 17, 2025, 8:03 AM EST - 8 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

Nov 12, 2025, 8:31 AM EST - 9 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

Nov 10, 2025, 8:03 AM EST - 9 months ago

HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

Oct 20, 2025, 8:03 AM EDT - 9 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

NRx Pharmaceuticals Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Oct 8, 2025, 9:30 AM EDT - 10 months ago

NRx Pharmaceuticals Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

Oct 6, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

Sep 29, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Sep 24, 2025, 8:03 AM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

NRx Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 4:30 PM EDT - 11 months ago

NRx Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

Sep 8, 2025, 8:17 AM EDT - 11 months ago

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Sep 3, 2025, 8:03 AM EDT - 11 months ago

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

Sep 2, 2025, 1:19 PM EDT - 11 months ago

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

Sep 2, 2025, 8:41 AM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

Aug 27, 2025, 8:03 AM EDT - 11 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

NRx Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 1 year ago

NRx Pharmaceuticals Earnings Call Transcript: Q2 2025

NRx Pharmaceuticals Earnings release: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 1 year ago

NRx Pharmaceuticals Earnings release: Q2 2025

NRx Pharmaceuticals Quarterly report: Q2 2025

Aug 20, 2025, 8:00 AM EDT - 1 year ago

NRx Pharmaceuticals Quarterly report: Q2 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 18, 2025, 8:10 AM EDT - 1 year ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Aug 13, 2025, 6:06 PM EDT - 1 year ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Tide16
Tide16 Jul. 23 at 12:43 AM
$NRXP Back at it tomorrow, keep the faith!
0 · Reply
Starwanderer
Starwanderer Jul. 22 at 8:26 PM
$NRXP https://www.digitaljournal.com/pr/news/pr-zen/darpa-selects-nrx-pharmaceuticals-defense-133556921.html
2 · Reply
biotrade123
biotrade123 Jul. 22 at 8:00 PM
$NRXP Good Close 👍👍🤞🤞
0 · Reply
biotrade123
biotrade123 Jul. 22 at 6:15 PM
$NRXP giving up gains??
0 · Reply
Outcomes
Outcomes Jul. 22 at 5:27 PM
$NRXP
0 · Reply
djcal
djcal Jul. 22 at 3:24 PM
$NRXP Getting a lot of news and attention NOW. Trial opens for US mum who says postpartum issues led her to killing own children https://www.bbc.com/news/articles/cy8e9jq1lzvo
0 · Reply
LuziusSteiger
LuziusSteiger Jul. 22 at 3:02 PM
$NRXP FDA continues its heavy crackdown on illicit/unapproved Ketamine suppliers! 🚨 > Another Warning Letter dropped (MARCS-CMS 725150) targeting grey-market IV/Inj Ketamine vendors. FDA explicitly highlighting the severe risks of unapproved injectables. The FDA is actively purging the market of illegal & unmonitored supply, effectively paving the way and building a massive moat for fully compliant, cGMP-grade formulations like KETAFREE™ / NRX-100. Clean market + Regulatory enforcement = Massive win for approved pharma. July 29 GDUFA date ahead! 🐂💊
0 · Reply
BioRich
BioRich Jul. 22 at 2:19 PM
$NRXP DARPA (free) money? Let's go $NRXP "On July 21, 2026, NRXD received a letter from the Defense Advanced Research Projects Agency (“DARPA”), Defense Sciences Office (DSO), notifying the Company that its proposal to conduct a clinical trial, entitled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) had been selected by DARPA for negotiation of a potential award." Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $NRXS
1 · Reply
BioRich
BioRich Jul. 22 at 2:16 PM
$NRXP Amazing news out of the $NRXP camp this morning. Anytime alternate funding opportunities arise, it's great for a company (and it's shareholders). Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! https://ir.nrxpharma.com/node/11201/html
1 · Reply
djcal
djcal Jul. 22 at 2:07 PM
$NRXP Your a fool if you sell after FDA approval. Other catalyst and you will miss out on the FREE shares of spin-off with Hope Therapeutics. Does anyone INVEST these days or is everything just a penny flip or treated with the stupid "Buy the rumor sell the news" motto. Everyone always taking a penny over a dollar just becaue they can't wait. Buffett 101: "The stock market is a device used to transfer money from the IMPATIENT to the PATIENT.
3 · Reply
Dubbyy
Dubbyy Jul. 22 at 1:54 PM
$NRXP very very bullish it will soon explode
0 · Reply
GeneralPatton46
GeneralPatton46 Jul. 22 at 1:51 PM
$NRXP
0 · Reply
GeneralPatton46
GeneralPatton46 Jul. 22 at 1:48 PM
$NRXP
0 · Reply
Saqer991
Saqer991 Jul. 22 at 1:47 PM
$NRXP 5$ ⏳ 6$ optimistic
0 · Reply
Tide16
Tide16 Jul. 22 at 1:30 PM
$NRXP Let's get to $5.00 today!
0 · Reply
jonny80s
jonny80s Jul. 22 at 1:13 PM
$NRXP we might see $5-6 on approval. Most likely short lived. Depends on what other news Javitt decides to bless shareholders with. There are lots of overdue items that management needs to update shareholders on. With the q2 review in mid August Javitt will have to come out of hiding. Next catalyst after q2 results and management speaking is the 3yr stability results for ketafree/100 that will be available mid to late September.
1 · Reply
DavidBG
DavidBG Jul. 22 at 12:08 PM
$NRXP DARPA is nearly at the point of signing off on the trial of TMS with NRX-101.
1 · Reply
kkreide
kkreide Jul. 22 at 11:41 AM
$NRXP I think it is a given that KETAFREE gets approved next week. The question is will the stock go up or down?? The company said it was going to submit an NDA for NRX-100 by 30 June but that obviously did not happen. My original plan was to hold the stock until the NRX-100 PDUFA date but now I am not sure if I should hold or sell. Thoughts??
4 · Reply
Lunatics
Lunatics Jul. 22 at 11:39 AM
$NRXP https://www.sec.gov/ix?doc=/Archives/edgar/data/1719406/000143774926024037/nrxp20260722_8k.htm
1 · Reply
Dubbyy
Dubbyy Jul. 22 at 11:33 AM
$NRXP https://tipranks.onelink.me/WJho/g0fwtyfp
0 · Reply
Dubbyy
Dubbyy Jul. 22 at 11:33 AM
$NRXP https://tipranks.onelink.me/WJho/g0fwtyfp
0 · Reply
jonny80s
jonny80s Jul. 22 at 10:49 AM
$NRXP 1 week away. It has been a long time coming: actual progress. Hopefully after the GDUFA we can get some feedback from management as to why the other pipelines have completely stalled and missed their timelines.
0 · Reply